IPI-145 in subjects with refractory iNHL

• Research type

  Research Study

• Full title

  A Phase 2 Study of IPI-145 in Subjects with Refractory Indolent Non-Hodgkin Lymphoma

• IRAS ID

  142883

• Contact name

  Hendrik-Tobias Arkenau

• Contact email

  Tobias.Arkenau@hcahealthcare.co.uk

• Sponsor organisation

  Infinity Pharmaceuticals, Inc.

• Eudract number

  2013-004008-20

• Clinicaltrials.gov Identifier

  NCT01882803

• Research summary

  This phase 2 study is being done in research subjects diagnosed with advanced forms of blood cancer whose disease has come back after treatment with the standard of care - rituximab and chemotherapy combined or radioimmunotherapy (RIT). Subjects would have been specifically diagnosed with indolent non-Hodgkin lymphoma (iNHL)(defined as follicular lymphoma [FL], marginal zone lymphoma [MZL; splenic, nodal and extranodal], or small lymphocytic lymphoma [SLL]). The primary objective of this trial is to evaluate the whether IPI-145 may be useful in treating hematologic blood) cancers like lymphoma, leukemia or myeloma.

• REC name

  London - London Bridge Research Ethics Committee

• REC reference

  13/LO/1886

• Date of REC Opinion

  13 Jan 2014

• REC opinion

  Further Information Favourable Opinion